Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Idiopathic Focal Segmental Glomerulosclerosis”

41 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 41 results

Testing effectiveness (Phase 2)Ended earlyNCT05441826
What this trial is testing

Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Minimal Change DiseaseFocal Segmental Glomerulosclerosis
Tenet Medicines 1
Post-approval studies (Phase 4)Study completedNCT02633046
What this trial is testing

Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria

Who this might be right for
Idiopathic Focal Segmental Glomerulosclerosis
Mallinckrodt ARD LLC 63
Large-scale testing (Phase 3)Looking for participantsNCT07220083
What this trial is testing

Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Focal Segmental Glomerulosclerosis
Boehringer Ingelheim 286
Testing effectiveness (Phase 2)Looking for participantsNCT06466135
What this trial is testing

Study of WAL0921 in Patients With Glomerular Kidney Diseases

Who this might be right for
Diabetic NephropathiesPrimary Focal Segmental GlomerulosclerosisMinimal Change Disease+2 more
Walden Biosciences 96
Not applicableLooking for participantsNCT04065438
What this trial is testing

Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System

Who this might be right for
Focal Segmental Glomerulosclerosis
Kaneka Medical America LLC 35
Early research (Phase 1)Study completedNCT00464321
What this trial is testing

Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

Who this might be right for
Focal Segmental Glomerulosclerosis
Genzyme, a Sanofi Company 16
Testing effectiveness (Phase 2)Study completedNCT00814255
What this trial is testing

Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial

Who this might be right for
Focal Segmental Glomerulosclerosis
NYU Langone Health 32
Not applicableLooking for participantsNCT04924712
What this trial is testing

INS, B Cells and Microbiota

Who this might be right for
MicrobiotaB-lymphocytesGlomerulosclerosis+1 more
Nantes University Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT06500702
What this trial is testing

Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Who this might be right for
Focal Segmental GlomerulosclerosisGlomerulonephritis Minimal Lesion
Sanofi 84
Large-scale testing (Phase 3)Study completedNCT03493685
What this trial is testing

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Focal Segmental Glomerulosclerosis
Travere Therapeutics, Inc. 371
Large-scale testing (Phase 3)UnknownNCT02896270
What this trial is testing

Valproic Acid for Idiopathic Nephrotic Syndrome

Who this might be right for
Idiopathic Nephrotic SyndromeFocal Segmental GlomerulosclerosisMinimal Change Disease
Universitair Ziekenhuis Brussel 15
Testing effectiveness (Phase 2)Study completedNCT01665391
What this trial is testing

Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Primary Focal Segmental Glomerulosclerosis
Genzyme, a Sanofi Company 36
Testing effectiveness (Phase 2)Study completedNCT02000440
What this trial is testing

A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)

Who this might be right for
Glomerulosclerosis, Focal Segmental
GlaxoSmithKline 17
Not applicableStudy completedNCT00255398
What this trial is testing

Kidney Disease Biomarkers

Who this might be right for
Kidney DiseaseGlomerular DiseaseIdiopathic Nephrotic Syndrome+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 25
Testing effectiveness (Phase 2)Study completedNCT01613118
What this trial is testing

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

Who this might be right for
Focal Segmental Glomerulosclerosis
Travere Therapeutics, Inc. 109
Testing effectiveness (Phase 2)WithdrawnNCT05599815
What this trial is testing

Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome

Who this might be right for
Nephrotic Syndrome
Aldeyra Therapeutics, Inc.
Not applicableStudy completedNCT04369183
What this trial is testing

Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease

Who this might be right for
Focal Segmental GlomerulosclerosisMinimal Change Disease
Istanbul University 25
Testing effectiveness (Phase 2)Study completedNCT04983888
What this trial is testing

Obinutuzumab in Primary FSGS

Who this might be right for
Primary Focal Segmental Glomerulosclerosis
Mayo Clinic 20
Large-scale testing (Phase 3)Study completedNCT00404833
What this trial is testing

Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental

Who this might be right for
Glomerulonephritis, MembranousGlomerulosclerosis, Focal
Hospital Authority, Hong Kong 16
Testing effectiveness (Phase 2)Looking for participantsNCT06664814
What this trial is testing

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis

Who this might be right for
Focal Segmental Glomerulosclerosis
National Human Genome Research Institute (NHGRI) 30
Load More Results